Low- vs. Normal-Flow Anesthesia and Delirium After Hip Fracture in the Elderly
Launched by GAZIOSMANPASA RESEARCH AND EDUCATION HOSPITAL · May 14, 2025
Trial Information
Current as of July 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how two different types of anesthesia—low-flow and normal-flow—affect the likelihood of developing delirium in elderly patients who are having surgery for hip fractures. Delirium is a sudden change in mental state, which can be confusing and distressing. The goal is to see if one type of anesthesia might help reduce the risk of this condition after surgery.
To participate in the study, you need to be at least 65 years old and scheduled for hip surgery. You should be generally healthy enough for surgery, but certain health issues like severe neurological diseases, recent surgeries, or difficulties with anesthesia may prevent you from joining. If you do participate, you’ll receive either low-flow or normal-flow anesthesia during your surgery, and researchers will monitor you afterwards to see how you respond. This study is important because understanding the best anesthesia approach could help improve recovery for elderly patients after hip surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 65 years and older who are scheduled to undergo surgical treatment for hip fracture, classified as ASA physical status I-IV, and who have signed the informed consent form will be included in the study.
- Exclusion Criteria:
- • Patients with complex fractures (multiple fractures, extremity, abdominal, pelvic or sacral trauma, head trauma, etc.), those with relative contraindications to general anesthesia (e.g., known difficult airway, malignant hyperthermia), patients requiring postoperative intubated intensive care follow-up, those with a history of dementia, sleep disorders, or psychosis, individuals with serious neurological diseases (e.g., Parkinson's disease, stroke sequelae), those with a history of opioid, alcohol, or substance use, patients with cerebrovascular disease, those who underwent surgery within the past 6 months, patients with hearing or vision impairment, bleeding disorders or those taking medications affecting coagulation, patients with hypoalbuminemia (\<3 g/dL), preoperative anemia with hematocrit \<30%, known allergy to anesthetic drugs, severe cardiopulmonary failure, immobility, malnutrition, or those who are unable to comply with the study protocol will be excluded from the study.
About Gaziosmanpasa Research And Education Hospital
Gaziosmanpasa Research and Education Hospital is a leading healthcare institution dedicated to advancing medical research and education. With a commitment to innovative clinical practices, the hospital serves as a hub for clinical trials aimed at improving patient outcomes and enhancing therapeutic options. The institution fosters collaboration among multidisciplinary teams, integrating cutting-edge research with exceptional patient care. By prioritizing ethical standards and regulatory compliance, Gaziosmanpasa Research and Education Hospital is poised to contribute significantly to the field of medical science and the development of new treatment modalities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported